Guided Therapeutics (GTHP) Gross Margin (2010 - 2025)
Guided Therapeutics recorded quarterly Gross Margin of 77.63% in Q4 2025, up 33.08% quarter-over-quarter from 58.33% in Q3 2025, and up 27763.0% year-over-year from N/an in Q4 2024.
Guided Therapeutics' Gross Margin history runs 16 years deep, the most recent figure standing at 77.63% for Q4 2025.
- In Q4 2025, Gross Margin rose 27763.0% year-over-year to 77.63%; the TTM figure through Dec 2025 stood at 74.58% (up 4600.0% YoY), while the FY2025 annual figure was 74.45%, up 4587.0% from the prior year.
- Gross Margin came in at 77.63% for Q4 2025 at Guided Therapeutics, up from 58.33% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 100.0% in Q2 2021 to a low of 200.0% in Q4 2024.
- A 5-year average of 36.54% and a median of 67.09% in 2024 frame the typical range for Gross Margin.
- Across the five-year window, Gross Margin tumbled 27167 bps in 2021 and jumped 27763 bps in 2025, its largest moves.
- Guided Therapeutics' Gross Margin stood at 68.33% in 2021, then soared by 46 bps to 100.0% in 2022, then sank by 50 bps to 50.0% in 2023, then slumped by 500 bps to 200.0% in 2024, then jumped by 139 bps to 77.63% in 2025.
- According to Business Quant data, Gross Margin over the past three periods registered 77.63%, 58.33%, and 67.52% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 56.20% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 63.29% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 63.83% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 69.46% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 78.01% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 45.22% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 62.95% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 38.53% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 43.89% |
| 10 | Guided Therapeutics | - | - | 458,000.00 | 77.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 77.63% |
| Sep 30, 2025 | 58.33% |
| Jun 30, 2025 | 67.52% |
| Dec 31, 2024 | -200.00% |
| Mar 31, 2024 | 66.67% |
| Dec 31, 2023 | 50.00% |
| Jun 30, 2023 | 25.00% |
| Mar 31, 2023 | 59.09% |
| Sep 30, 2022 | 100.00% |
| Jun 30, 2022 | 80.00% |
| Mar 31, 2022 | 80.00% |
| Dec 31, 2021 | 68.33% |
| Sep 30, 2021 | -121.05% |
| Jun 30, 2021 | 100.00% |
| Dec 31, 2020 | 340.00% |
| Sep 30, 2020 | 84.42% |
| Dec 31, 2019 | 75.00% |
| Sep 30, 2019 | 100.00% |
| Jun 30, 2019 | -6,400.00% |
| Mar 31, 2019 | 94.44% |
| Dec 31, 2018 | -104.76% |
| Sep 30, 2018 | 100.00% |
| Jun 30, 2018 | 87.50% |
| Mar 31, 2018 | 25.00% |
| Dec 31, 2017 | -213.08% |
| Sep 30, 2017 | -193.94% |
| Jun 30, 2017 | 5.75% |
| Mar 31, 2017 | 23.81% |
| Dec 31, 2016 | 38.89% |
| Sep 30, 2016 | 10.53% |
| Dec 31, 2015 | 2,388.89% |
| Sep 30, 2015 | -1,600.00% |
| Jun 30, 2015 | -1,040.00% |
| Mar 31, 2015 | 133.33% |
| Dec 31, 2014 | 30.77% |
| Sep 30, 2014 | 9.09% |
| Jun 30, 2014 | -636.36% |
| Mar 31, 2014 | -368.42% |
| Dec 31, 2013 | -47.40% |
| Sep 30, 2013 | -68.60% |
| Jun 30, 2013 | -1.35% |
| Mar 31, 2013 | -15.57% |
| Dec 31, 2012 | 1.28% |
| Sep 30, 2012 | -1.73% |
| Jun 30, 2012 | -5.03% |
| Mar 31, 2012 | 90.25% |
| Dec 31, 2011 | 110.49% |
| Sep 30, 2011 | 92.16% |
| Jun 30, 2011 | 92.22% |
| Mar 31, 2011 | 93.61% |
| Jun 30, 2010 | 94.53% |